European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C
Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
You may be interested
Regling: “We are ready to ease the Greek debt”makis - Feb 23, 2018
Technical work has begun to determine whether Greece will need a debt relief after an expected exit from the rescue…
Turkey threatens violence against Italian drill ship anew in Cyprus!makis - Feb 23, 2018
Turkey continued its belligerent stance off the coast of Cyprus on Friday, as it openly threatened violence against the Italian…
Greek PM Tsipras met with German Chancellor Merkel on EU Summit sidelinesmakis - Feb 23, 2018
Greek PM Alexis Tsipras met with German Chancellor Angela Merkel on the sidelines of the Brussels EU Summit, Thursday. According…